- In early April 2026, Alkermes plc announced it had begun the Brilliance phase 3 program, a set of randomized, double-blind, placebo-controlled studies testing its oral orexin 2 receptor agonist alixorexton in adults with narcolepsy type 1 and type 2, following earlier phase 1 and phase 2 work and Breakthrough Therapy designation in narcolepsy type 1.
- The launch of these Brilliance Studies signals Alkermes’ intention to build a differentiated sleep-disorder franchise around orexin agonism, potentially extending beyond narcolepsy into broader hypersomnolence conditions if longer-term safety and efficacy data support additional indications.
- We’ll now examine how the phase 3 Brilliance program for alixorexton could influence Alkermes’ sleep-franchise thesis and broader investment narrative.
Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
Alkermes Investment Narrative Recap
To own Alkermes today, you have to believe its transition from a concentrated psychiatry portfolio toward a broader orexin-based sleep franchise can offset softer recent financials and rising R&D spend. The Brilliance phase 3 launch crystallizes alixorexton as the key near term catalyst, while trial, regulatory and safety uncertainties around this program remain the most important risk. This news is material because it moves the orexin story firmly into late stage execution.
The most directly relevant recent announcement is the FDA’s Breakthrough Therapy designation for alixorexton in narcolepsy type 1, granted in January 2026. That decision, based on earlier phase 1 and 2 data, had already positioned alixorexton as a centerpiece of Alkermes’ future. With Brilliance now underway, investors are watching how this Breakthrough path, combined with phase 3 data and any label scope that follows, could reshape both the company’s growth profile and its risk concentration.
Yet investors should also weigh how rising R&D costs and a small set of core products leave Alkermes exposed if Brilliance outcomes or safety findings...
Read the full narrative on Alkermes (it's free!)
Alkermes’ narrative projects $2.1 billion revenue and $245.7 million earnings by 2029.
Uncover how Alkermes' forecasts yield a $43.71 fair value, a 25% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were already modeling roughly US$1.7 billion of revenue and US$276.3 million of earnings by 2028, but the Brilliance phase 3 start could either reinforce that bullish view or highlight how much depends on a single late stage asset and why reasonable investors may reach very different conclusions about Alkermes’ next chapter.
Explore 5 other fair value estimates on Alkermes - why the stock might be worth just $38.20!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Alkermes research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Alkermes research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alkermes' overall financial health at a glance.
Looking For Alternative Opportunities?
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
- AI is about to change healthcare. These 37 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com